Resumen

Renal failure in cirrhotic patients is a very severe condition. Hepatorenal syndrome has the worst prognosis among all causes of kidney failure in such patients. Hepatorenal syndrome is diagnosed especially in cirrhotic patients with ascites who develop loss renal function, despite diuretic suspension and volume expansion with albumin and for whom other causes of kidney injury have been excluded. Patients with hepatorenal syndrome should be treated with a vasoconstrictor in combination with albumin as a bridge to receiving a liver transplant. The vasoconstrictor of choice is terlipressin or noradrenaline. In spite of higher drug-related costs associated to terlipressin, initial evidence demonstrates that, considering all direct medical costs involved, the treatment strategy using terlipressin is probably more economical than that using noradrenaline.

Palabras clave: Cirrhosis acute kidney injury terlipressin noradrenaline albumin.

2016-06-23   |   380 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.4. Julio-Agosto 2016 Pags. 474-481 Ann Hepatol 2016; 15(4)